Agenus to Report Third Quarter 2014 Financial Results on October 31, 2014; Conference Call to Follow
October 27 2014 - 7:00AM
Business Wire
Agenus Inc. (NASDAQ: AGEN) will report its third quarter 2014
financial results before the market opens on Friday, October 31,
2014.
Agenus executives will host a conference call at 11 a.m. Eastern
Time the same day. To access the live call, dial 416-640-5946. The
call will also be webcast and will be accessible from the company’s
website at www.agenusbio.com/webcast/. A replay will be available
on the company’s website approximately two hours after the call and
will remain available for 60 days. The replay number is
416-915-1035, and the access code is 543876.
About Agenus
Agenus is an immuno-oncology company developing a portfolio of
checkpoint modulators (CPMs), heat shock protein peptide vaccines
and adjuvants. Agenus’ checkpoint modulator programs target GITR,
OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary
discovery engine Retrocyte Display® is used to generate fully human
and humanized therapeutic antibody drug candidates. The Retrocyte
Display platform uses a high-throughput approach incorporating IgG
format human antibody libraries expressed in mammalian B-lineage
cells. Agenus’ heat shock protein vaccines for cancer and
infectious disease are in Phase 2 studies. The company’s QS-21
Stimulon® adjuvant platform is extensively partnered with
GlaxoSmithKline and Janssen and includes several candidates in
Phase 3 trials. For more information, please visit
www.agenusbio.com, or connect with the company on Facebook,
LinkedIn, Twitter and Google+.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding the Company’s anticipated timing for
reporting its third quarter 2014 financial results. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission for the period
ended June 30, 2014. Agenus cautions investors not to place
considerable reliance on the forward-looking statements contained
in this release. These statements speak only as of the date of this
document, and Agenus undertakes no obligation to update or revise
the statements. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. Agenus’
business is subject to substantial risks and uncertainties,
including those identified above. When evaluating Agenus’ business
and securities, investors should give careful consideration to
these risks and uncertainties.
BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024